Trial reportNeuropsychiatric disease and treatment2025
Magnetic Seizure Therapy vs Electroconvulsive Therapy in Schizophrenia: Prefrontal-Amygdala Plasticity and Cognitive Safety.
Trial report in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02746965 (Magnetic Seizure Therapy for Schizophrenia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Magnetic Seizure Therapy for Schizophrenia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Reducing electroconvulsive therapy (ECT)'s cognitive burden without compromising efficacy is critical. Although magnetic seizure therapy (MST) shows comparable symptom remission in schizophrenia, its neuroanatomical safety-particularly limbic preservation-lacks controlled trial validation. Patients and Methods: This triple-blind RCT (NCT02746965) randomized 34 schizophrenia patients to ECT (n=16) or MST (n=18). Structural changes were quantified via 3T MRI (FreeSurfer). Outcomes included Positive and Negative Syndrome Scale (PANSS), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and generalized linear mixed-effects models with FDR correction (q<0.1). Results: Both groups achieved comparable PANSS reduction (ECT: Δ=-38.2±5.1 vs MST: Δ=-35.7±6.4, p=0.12). MST showed superior cognitive preservation vs ECT in language (Δ=+7.2 vs ECT: Δ=-3.1; Cohen's d=1.15, p=0.003) and delayed memory (Δ=+5.8 vs +1.2, p=0.04). Nonsignificant between-group differences in amygdala volume changes (ECT: Δ= -1.2% vs -0.9%, p = 0.31). Conclusion: As the first RCT mapping neuroanatomical changes of convulsive therapies in schizophrenia, we establish MST's cognitive safety via prefrontal-amygdala plasticity-a novel mechanism preserving language and memory functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.